Thursday, August 8, 2013
Cleveland Biolabs Inc., of Buffalo, N.Y., began enrolling in a Phase I trial of CBL0137, for metastatic or unresectable advanced solid cancers and lymphomas.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.